Short News

Print

short news

Rebamipide-induced downregulation of
phospholipase D inhibits inflammation
and proliferation in gastric cancer cells

Dong Woo Kang, Gyesik Min, Do Yoon Park,
Ki Whan Hong and Do Sik Min

Abstract: Rebamipide a gastroprotective drug, is clinically used for the treatment of gastric ulcers and gastritis, but its actions on gastric cancer are not clearly understood. Phospholipase D (PLD) is overexpressed in various types of cancer tissues and has been implicated as a critical factor in inflammation and carcinogenesis. However, whether rebamipide is involved in the regulation of PLD in gastric cancer cells is not known. In this study, we showed that rebamipide significantly suppressed the expression of both PLD1 and PLD2 at a transcriptional level in AGS and MKN-1 gastric cancer cells. Downregulation of PLD expression by rebamipide inhibited its enzymatic activity. In addition, rebamipide inhibited the transactivation of nuclear factor kappa B (NFκB), which increased PLD1 expression. Rebamipide or PLD knockdown significantly suppressed the expression of genes involved in inflammation and proliferation and inhibited the proliferation.(PR)

Ref: Experimental and Molecular Medicine, Vol. 42, No. 8, 555-564, August 2010.

© Professional Medical Publications. All rights reserved.